Compare Danaher Corporation (DHR) vs S&P500 ETF (SPY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs S&P500 ETF — how do they compare? Danaher Corporation trades at $204.2 (market cap $145.83B), while S&P500 ETF trades at $772.77. The key difference: Danaher Corporation pays a 0.77% dividend while S&P500 ETF pays none, and S&P500 ETF is trading nearer its 52-week high, Danaher Corporation nearer its low. Which is the better fit depends on your goals.
| DHR | SPY | |
|---|---|---|
Market Cap | $145.83B | — |
Sector | Health | — |
52-Week High | $242.05 | $773.22 |
52-Week Low | $161.91 | $631.99 |
Enterprise Value | $168.04B | — |
Dividend Yield | 0.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
SPY, the SPDR S&P 500 ETF Trust, trades at $773.08 with minimal daily change, reflecting stability near record highs. Technical indicators show a bullish trend with strong moving average signals, though oscillators are neutral and RSI levels suggest overbought conditions. The ETF remains a core holding for broad U.S. equity exposure, with a dividend scheduled for July 2026. Market sentiment is mixed, balancing optimism from AI-driven gains against concerns over elevated valuations.
The outlook for SPY hinges on sustained earnings growth and macroeconomic factors, with upside potential if corporate profits meet expectations. Risks include high valuation multiples, potential interest rate shifts, and geopolitical tensions. Institutional analysts monitor inflation data and earnings revisions for directional cues, with the ETF's low expense ratio and liquidity supporting its appeal for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →
